2023 World Conference on Lung Cancer (Posters)-P2.21. Inflammatory Biomarkers as Prognostic Factors for Malignant Pleural Mesothelioma

Pdf Summary

Malignant pleural mesothelioma is a type of cancer that affects the membranes lining the lungs and thoracic cavity. It is primarily caused by exposure to asbestos, high-dose radiation, mineral fibers, or chronic serosal inflammatory conditions. Common symptoms include chest pain, shortness of breath, dry cough, weight loss, fatigue, masses under the chest skin, and pleural effusions.<br /><br />The purpose of this study was to identify inflammatory biomarkers that can serve as prognostic indicators for malignant pleural mesothelioma. The researchers analyzed data from patients enrolled in the National Cancer Institute's protocol NCT 01950572, which recorded the natural history of malignant mesothelioma patients. Blood samples were taken from these patients, and six biomarkers were analyzed: MESOMARK, CA125, C-reactive protein, neutrophil-to-lymphocyte ratio, fibrinogen, and platelet count.<br /><br />The primary outcome measured was the median overall survival of the patients. The patients were divided into quartiles based on the biomarker values, and the middle two quartiles were combined due to similar survival results. The overall survival of the different groups was compared using Kaplan-Meier curves.<br /><br />The study found that there is currently only one FDA-approved diagnostic biomarker for pleural mesothelioma, which is the soluble mesothelin-related peptide (MESOMARK) measured by the MESOMARK assay. However, the sensitivity of this biomarker is only 64%.<br /><br />Other prognostic indicators for malignant pleural mesothelioma identified in previous studies include the lymphocyte-to-monocyte ratio (LMR), age, duration of environmental asbestos exposure, ECOG performance status, gender, histology, leukocyte count, and osteopontin levels.<br /><br />In conclusion, this study aimed to develop a prognostic scoring model for malignant pleural mesothelioma to aid in making therapeutic decisions. The researchers analyzed several biomarkers and their impact on overall survival. The findings highlight the need for more effective diagnostic and prognostic biomarkers for this aggressive malignancy.

Asset Subtitle

Keval Yerigeri

Meta Tag

Speaker Keval Yerigeri

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Translational

Keywords

malignant pleural mesothelioma

cancer

asbestos exposure

radiation

inflammatory biomarkers

prognostic indicators

MESOMARK

diagnostic biomarker

overall survival

therapeutic decisions